Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248329 | 0.92 | ESR2 (0.53) | ESR2ESR1 | |
| SCHEMBL12893336 | 0.86 | ESR1 (0.39) | ESR2ESR1ACHEOPRM1 | |
| SCHEMBL1255425 | 0.86 | ESR2 (0.47) | ESR2ESR1MAOBMAOATRPA1 | |
| SCHEMBL14260542 | 0.86 | ESR2 (0.47) | ESR2ESR1MAOBMAOATRPA1 | |
| SCHEMBL12893332 | 0.86 | ESR2 (0.47) | ESR2ESR1OPRM1KMT2A | |
| SCHEMBL25767034 | 0.86 | ESR2 (0.47) | ESR2ESR1ACHEMAOBMAOA | |
| SCHEMBL1256648 | 0.86 | ESR2 (0.47) | ESR2ESR1OPRM1KMT2A | |
| SCHEMBL12893312 | 0.83 | ESR2 (0.40) | ESR2ESR1ACHEACACBACACA | |
| SCHEMBL14531518 | 0.81 | ESR2 (0.42) | ESR2ESR1ACACBACACA | |
| SCHEMBL2248696 | 0.81 | CA2 (0.46) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | ESR2 1/4885ESR1 2/4885ACHE 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.